Aaron Tachibana, holding the dual roles of Chief Financial Officer and Chief Operating Officer at Personalis, Inc. (NASDAQ: PSNL), executed a significant divestment of company equity on June 26, 2026. The transaction involved the sale of 51,251 shares of common stock, generating proceeds of approximately $675,488. This disposition occurred on the same day that Tachibana exercised stock options to acquire an equivalent number of shares, highlighting a complex sequence of equity management activities.
The shares were sold at a weighted average price of $13.18, with individual transaction prices varying between $13.00 and $13.30 per share. This sale activity took place while the stock was trading near its 52-week high of $13.37, a period marked by a substantial 98% return over the preceding year. Market analysis indicates that the stock may currently be overvalued relative to its fair value, with additional proprietary insights available to subscribers.
Earlier in the day, Tachibana acquired shares through the exercise of stock options. He purchased 28,832 shares at a price of $9.16 per share and an additional 22,419 shares at $5.32 per share. The total acquisition cost for these options was approximately $383,370. All shares subject to these exercises were fully vested and exercisable, allowing for immediate liquidity upon conversion.
Both the option exercises and the subsequent stock sales were executed in accordance with a Rule 10b5-1 trading plan adopted by Tachibana on August 7, 2025. This pre-arranged framework is designed to facilitate trading in compliance with securities regulations while mitigating the appearance of insider trading. Following these transactions, Tachibana directly holds 198,833 shares of Personalis common stock.
In parallel with executive trading activity, Personalis reported significant operational milestones in its first-quarter financial performance. Revenue surpassed internal and external expectations, driven by strong adoption of its NeXT Personal MRD test. The test volume experienced a 258% year-over-year increase and a 26% quarter-over-quarter jump, with over 1,000 oncologists placing orders during the quarter.
Regulatory and coverage expansions further bolstered the company's market position. Personalis announced expanded Medicare coverage for the NeXT Personal test, now including monitoring of treatment response to neoadjuvant therapy in patients with specific types of breast cancer. Additionally, the coverage now supports immunotherapy monitoring for patients with late-stage solid tumors. This expansion marks a notable milestone, enhancing the test's applicability across diverse treatment settings.
Internationally, Personalis received Class A CE-IVD marking for its blood collection kits under the European Union’s In Vitro Diagnostic Regulation. This approval permits the use of these kits in clinical trials across the EU and Great Britain, supporting the company's broader genomic analysis initiatives, including Minimal Residual Disease testing.
Corporate governance activities also proceeded recently, with Personalis holding its 2026 annual meeting of stockholders virtually. A quorum was established with 87.76% of outstanding shares represented. Despite these operational advances, BTIG, an analyst firm, adjusted its price target for Personalis from $13 to $11. The firm maintained a Buy rating, reflecting broader sector valuation considerations that may impact investor sentiment.